


Re'd PTO 01 APR 2003



PA 1074962

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

October 06, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/475,784

FILING DATE: June 05, 2003

PRIORITY  
DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

  
E. BORNETT  
Certifying Officer

BEST AVAILABLE COPY

6045734-060504/PRO

PTO/SB/16 (10-01)

Approved for use through 10/31/2002. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No.

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Bent Karsten Jonathan Michael	JAKOBSEN BOULTER	Oxfordshire, England Oxfordshire, England

 Additional inventors are being named on the 1 separately numbered sheets attached hereto**TITLE OF THE INVENTION (500 characters max)****RECEPTORS****CORRESPONDENCE ADDRESS**

Direct all correspondence to:

 Customer Number

22907

Place Customer Number  
Bar Code Label here

OR

Type Customer Number here

 Firm or  
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

**ENCLOSED APPLICATION PARTS (check all that apply)** Specification Number of Pages

35

 CD(s), Number Drawing(s) Number of Sheets

8

 Other (specify) Application Data Sheet. See 37 CFR 1.76**METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT** Applicant claims small entity status. See 37 CFR 1.27. A check or money order is enclosed to cover the filing feesFILING FEE  
AMOUNT (\$) The Commissioner is hereby authorized to charge filing  
fees or credit any overpayment to Deposit Account Number:

19-0733

160

 Payment by credit card. Form PTO-2038 is attached.The invention was made by an agency of the United States Government or under a contract with an agency of  
the United States Government. No. Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_Respectfully submitted,  
SIGNATURE

Date

6/5/03

TYPED or PRINTED NAME

Susan A. Wolfe

REGISTRATION NO.

33,568

(if appropriate)

TELEPHONE

202-824-3000

Docket Number:

006090.00007

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

14772 U.S. PTO  
60/475784

**PROVISIONAL APPLICATION COVER SHEET**  
*Additional Page*

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0851-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number	006090.00007
---------------	--------------

**INVENTOR(S)/APPLICANT(S)**

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Meir	GLICK	Morristown, New Jersey

Number 2 of 2**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

## Application Data Sheet

### **Application Information**

**Application number::**

**Filing Date::**

**Application Type::**

**Provisional**

**Subject Matter::**

**Utility**

**Suggested classification::**

**Suggested Group Art Unit::**

**CD-ROM or CD-R?::**

**None**

**Number of CD disks::**

**Number of copies of CDs::**

**Sequence submission?::**

**Computer Readable Form (CRF)?::**

**Number of copies of CRF::**

**Title::**

**RECEPTORS**

**Attorney Docket Number::**

**006090.00007**

**Request for Early Publication?::**

**NO**

**Request for Non-Publication?::**

**NO**

**Suggested Drawing Figure::**

**Total Drawing Sheets::**

**8**

**Small Entity?::**

**NO**

**Latin name::**

**Variety denomination name::**

**Petition included?::**

**NO**

**Petition Type::**

**Licensed US Govt. Agency::**

**Contract or Grant Numbers::**

**Secrecy Order in Parent Appl.?::**

**NO**

**Applicant Information**

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Denmark  
Status:: Full Capacity  
Given Name:: Bent  
Middle Name:: Karsten  
Family Name:: JAKOBSEN  
Name Suffix::  
City of Residence::  
State or Province of Residence:: Oxfordshire  
Country of Residence:: England  
Street of mailing address::  
City of mailing address:: Oxfordshire  
State or Province of mailing address:: England  
Country of mailing address:: England  
Postal or Zip Code of mailing address::  
  
Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Great Britian  
Status:: Full Capacity  
Given Name:: Jonathan  
Middle Name:: Michael  
Family Name:: BOULTER  
Name Suffix::  
City of Residence::  
State or Province of Residence:: Oxfordshire  
Country of Residence:: England  
Street of mailing address::  
City of mailing address:: Oxfordshire  
State or Province of mailing address:: England

Country of mailing address:: England

Postal or Zip Code of mailing address::

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Israel

Status:: Full Capacity

Given Name:: Meir

Middle Name::

Family Name:: GLICK

Name Suffix::

City of Residence::

State or Province of Residence:: New Jersey

Country of Residence:: USA

Street of mailing address::

City of mailing address::

State or Province of mailing address:: New Jersey

Country of mailing address:: USA

Postal or Zip Code of mailing address::

### **Correspondence Information**

Correspondence Customer Number:: 22907

### **Representative Information**

Representative Customer Number:: 22907

### **Domestic Priority Information**

Application::	Continuity Type::	Parent Application::	Parent Filing Date::

--	--	--	--

**Foreign Priority Information**

Country::	Application number::	Filing Date::	Priority Claimed::

**Assignee Information****Assignee name::****Street of mailing address::****City of mailing address::****State or Province of mailing address::****Country of mailing address::****Postal or Zip Code of mailing address::**

## RECEPTORS

The present invention relates to single-chain T cell receptors (TCRs).

5      **Background to the Invention**

*Native TCRs*

As is described in, for example, WO 99/60120 TCRs mediate the recognition of specific Major Histocompatibility Complex (MHC)-peptide complexes by T cells and, as such, are essential to the functioning of the cellular arm of the immune system.

10

Antibodies and TCRs are the only two types of molecules which recognise antigens in a specific manner, and thus the TCR is the only receptor for particular peptide antigens presented in MHC, the alien peptide often being the only sign of an abnormality within a cell. T cell recognition occurs when a T-cell and an antigen presenting cell

15

(APC) are in direct physical contact, and is initiated by ligation of antigen-specific TCRs with pMHC complexes.

20

The native TCR is a heterodimeric cell surface protein of the immunoglobulin superfamily which is associated with invariant proteins of the CD3 complex involved in mediating signal transduction. TCRs exist in  $\alpha\beta$  and  $\gamma\delta$  forms, which are structurally similar but have quite distinct anatomical locations and probably functions. The MHC class I and class II ligands are also immunoglobulin superfamily proteins but are specialised for antigen presentation, with a highly polymorphic peptide binding site which enables them to present a diverse array of short peptide fragments at the APC cell surface.

25

Two further classes of proteins are known to be capable of functioning as TCR ligands. (1) CD1 antigens are MHC class I-related molecules whose genes are located on a different chromosome from the classical MHC class I and class II antigens. CD1 molecules are capable of presenting peptide and non-peptide (eg lipid, glycolipid) moieties to T cells in a manner analogous to conventional class I and class II-MHC-

30

pep complexes. See, for example (Barclay et al, (1997) *The Leucocyte Antigen Factsbook 2<sup>nd</sup> Edition*, Acadmeic Press) and (Bauer (1997) *Eur J Immunol* 27 (6) 1366-1373)) (2) Bacterial superantigens are soluble toxins which are capable of binding both class II MHC molecules and a subset of TCRs.(Fraser (1989) *Nature* 339 221-223) Many superantigens exhibit specificity for one or two Vbeta segments, whereas others exhibit more promiscuous binding. In any event, superantigens are capable of eliciting an enhanced immune response by virtue of their ability to stimulate subsets of T cells in a polyclonal fashion.

10 The extracellular portion of native heterodimeric  $\alpha\beta$ TCR consists of two polypeptides each of which has a membrane-proximal constant domain, and a membrane-distal variable domain (see Figure 1). Each of the constant and variable domains includes an intra-chain disulfide bond. The variable domains contain the highly polymorphic loops analogous to the complementarity determining regions (CDRs) of antibodies.

15 CDR3 of the TCR interacts with the peptide presented by MHC, and CDRs 1 and 2 interact with the peptide and the MHC. The diversity of TCR sequences is generated via somatic rearrangement of linked variable (V), diversity (D), joining (J), and constant genes. Functional  $\alpha$  chain polypeptides are formed by rearranged V-J-C regions, whereas  $\beta$  chains consist of V-D-J-C regions. The extracellular constant

20 domain has a membrane proximal region and an immunoglobulin region. There is a single  $\alpha$  chain constant domain, known as TRAC, and two different  $\beta$  constant domains, known as TRBC1 and TRBC2 (IMGT nomenclature). There are four amino acid changes between these  $\beta$  constant domains, three of which are within the domains used to produce the single-chain TCRs of the present invention. These changes are all within exon 1 of TRBC1 and TRBC2: N<sub>4</sub>K<sub>5</sub>->K<sub>4</sub>N<sub>5</sub> and F<sub>37</sub>->Y (IMGT numbering, differences TRBC1->TRBC2), the final amino acid change between the two TCR  $\beta$  chain constant regions being in exon 3 of TRBC1 and TRBC2: V<sub>1</sub>->E. The extent of each of the TCR extracellular domains is somewhat variable. However, a person skilled in the art can readily determine the position of the domain boundaries using a reference such as *The T Cell Receptor Facts Book*, Lefranc & Lefranc, Publ. Academic Press 2001.

*Single Chain TCRs*

Single-chain TCRs (scTCRs) are artificial constructs consisting of a single amino acid strand, which like native heterodimeric TCRs bind to MHC-peptide complexes.

5      Unfortunately, attempts to produce functional alpha/beta analogue scTCRs by simply linking the alpha and beta chains such that both are expressed in a single open reading frame have been unsuccessful, presumably because of the natural instability of the alpha-beta soluble domain pairing.

10     Accordingly, special techniques using various truncations of either or both of the alpha and beta chains have been necessary for the production of scTCRs. These formats appear to be applicable only to a very limited range of scTCR sequences. Soo Hoo *et al* (1992) PNAS. 89 (10): 4759-63 report the expression of a mouse TCR in single chain format from the 2C T cell clone using a truncated beta and alpha chain linked with a 25 amino acid linker and bacterial periplasmic expression (see also Schodin *et al* (1996) Mol. Immunol. 33 (9): 819-29). This design also forms the basis of the m6 single-chain TCR reported by Holler *et al* (2000) PNAS. 97 (10): 5387-92 which is derived from the 2C scTCR and binds to the same H2-Ld-restricted alloepitope. Shusta *et al* (2000) Nature Biotechnology 18: 754-759 report using single-chain 2 C TCR constructs in yeast display experiments, which produced mutated TCRs with, enhanced thermal stability and solubility. , this report also demonstrated the ability of these displayed 2C TCRs to selectively bind cells expressing their cognate pMHC. Khandekar *et al* (1997) J. Biol. Chem. 272 (51): 32190-7 report a similar design for the murine D10 TCR, although this scTCR was fused to MBP and expressed in bacterial cytoplasm (see also Hare *et al* (1999) Nat. Struct. Biol. 6 (6): 574-81). Hilyard *et al* (1994) PNAS. 91 (19): 9057-61 report a human scTCR specific for influenza matrix protein-HLA-A2, using a V $\alpha$ -linker-V $\beta$  design and expressed in bacterial periplasm.

20     25     30     Chung *et al* (1994) PNAS. 91 (26) 12654-8 report the production of a human scTCR using a V $\alpha$ -linker-V $\beta$ -C $\beta$  design and expression on the surface of a mammalian cell

line. This report does not include any reference to peptide-HLA specific binding of the scTCR. Plaksin *et al* (1997) *J. Immunol.* **158** (5): 2218-27 report a similar V $\alpha$ -linker-V $\beta$ -C $\beta$  design for producing a murine scTCR specific for an HIV gp120-H-2D $\delta$  epitope. This scTCR is expressed as bacterial inclusion bodies and refolded *in vitro*.

5

#### *Therapeutic Use*

There is a need for targeting moieties capable of localising to cells affected by disease processes. Such targeting moieties could be utilised either to directly block the 'mis-directed' action of the immune system responsible for auto-immune disease or as a 10 means of delivering cytotoxic agents to cancerous cells.

Ideally, molecules suitable for these applications require a specific affinity for a cell marker directly involved in the relevant disease process. Antibodies have been used for this purpose.

15

#### *Screening Use*

A number of important cellular interactions and cell responses, including the TCR-mediated immune synapse, are controlled by contacts made between cell surface receptors and ligands presented on the surfaces of other cells. These types of specific 20 molecular contacts are of crucial importance to the correct biochemical regulation in the human body and are therefore being studied intensely. In many cases, the objective of such studies is to devise a means of modulating cellular responses in order to prevent or combat disease.

25 Therefore, methods with which to identify compounds that bind with some degree of specificity to human receptor or ligand molecules are important as leads for the discovery and development of new disease therapeutics. In particular, compounds that interfere with certain receptor-ligand interactions have immediate potential as therapeutic agents or carriers.

30

Advances in combinatorial chemistry, enabling relatively easy and cost-efficient production of very large compound libraries, have increased the scope for compound testing enormously. Now the limitations of screening programmes most often reside in the nature of the assays that can be employed, the production of suitable receptor  
5 and ligand molecules and how well these assays can be adapted to high throughput screening methods.

**Brief Description of the Invention**

This invention makes available a new class of alpha/beta-analogue scTCRs which are  
10 characterised by the presence of a disulfide bond between residues of the single amino acid strand, that bond contributing to the stability of the pairing between alpha and beta regions of the molecule. Such TCRs are useful for screening or therapeutic purposes.

**15 Detailed Description of the Invention**

The present invention provides a single chain T cell receptor (scTCR) comprising an  $\alpha$  segment constituted by a TCR  $\alpha$  chain variable region sequence fused to the N terminus of a TCR  $\alpha$  chain constant region extracellular sequence, a  $\beta$  segment constituted by a TCR  $\beta$  chain variable region sequence fused to the N terminus of a  
20 TCR  $\beta$  chain constant region extracellular sequence, and a linker sequence linking the C terminus of the  $\alpha$  segment to the N terminus of the  $\beta$  segment, or vice versa, the constant region extracellular sequences of the  $\alpha$  and  $\beta$  segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the  $\alpha$  and  $\beta$  segments are mutually  
25 orientated substantially as in native  $\alpha\beta$  T cell receptors.

In the scTCR's of the invention the requirement that the variable region sequences of the  $\alpha$  and  $\beta$  segments are mutually orientated substantially as in native  $\alpha\beta$  T cell receptors is tested by confirming that the molecule binds to the relevant TCR ligand  
30 (pMHC complex, CD1-antigen complex, superantigen or superantigen/pMHC

complex) - if it binds, then the requirement is met. Interactions with pMHC complexes can be measured using a BIACore 3000™ or BIACore 2000™ instrument. Example 3 herein, or WO99/6120 respectively provide detailed descriptions of the methods required to analyse TCR binding to MHC-peptide complexes. These methods are 5 equally applicable to the study of TCR/ CD1 and TCR/superantigen interactions. In order to apply these methods to the study of TCR/CD1 interactions soluble forms of CD1 are required, the production of which are described in (Bauer (1997) Eur J Immunol 27 (6) 1366-1373).

10  *$\alpha$  and  $\beta$  Segments*

The constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments preferably correspond to those of a human TCR, as do the variable region sequences present in the  $\alpha$  and  $\beta$  segments. However, the correspondence between such sequences need not be 1:1 on an amino acid level. N- or C-truncation, and/or amino acid deletion and/or 15 substitution relative to the corresponding human TCR sequences is acceptable, provided the overall result is mutual orientation of variable region sequences of the  $\alpha$  and  $\beta$  segments as in native  $\alpha\beta$  T cell receptors and retention of peptide-MHC binding functionality. In particular, because the constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments are not directly involved in contacts with the peptide-MHC 20 complex to which the scTCR binds, they may be shorter than, or may contain substitutions or deletions relative to, extracellular constant domain sequences of native TCRs.

25 The constant region extracellular sequence present in the  $\alpha$  segment may include a sequence corresponding to the extracellular constant Ig domain of a TCR  $\alpha$  chain, and/or the constant region extracellular sequence present in the  $\beta$  segment may include a sequence corresponding to the extracellular constant Ig domain of a TCR  $\beta$  chain.

30 In one embodiment of the invention, the  $\alpha$  segment corresponds to substantially all the variable region of a TCR  $\alpha$  chain fused to the N terminus of substantially all the

extracellular domain of the constant region of an TCR  $\alpha$  chain; and/or the  $\beta$  segment corresponds to substantially all the variable region of a TCR  $\beta$  chain fused to the N terminus of substantially all the extracellular domain of the constant region of a TCR  $\beta$  chain .

5

In another embodiment, the constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to the constant regions of the  $\alpha$  and  $\beta$  chains of a native TCR truncated at their C termini such that the cysteine residues which form the native interchain disulfide bond of the TCR are excluded. Alternatively those cysteine 10 residues may be substituted by another amino acid residue such as serine or alanine, so that the native disulfide bond is deleted. In addition, the native TCR  $\beta$  chain contains an unpaired cysteine residue and that residue may be deleted from, or replaced by a non-cysteine residue in, the  $\beta$  sequence of the scTCR of the invention.

15

In one particular embodiment of the invention, the TCR  $\alpha$  and  $\beta$  chain variable region sequences present in the  $\alpha$  and  $\beta$  segments may together correspond to the functional variable domain of a first TCR, and the TCR  $\alpha$  and  $\beta$  chain constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments may correspond to those of a second TCR, the first and second TCRs being from the same species. Thus the  $\alpha$  and  $\beta$  20 chain variable region sequences present in the  $\alpha$  and  $\beta$  segments may correspond to those of a first human TCR, and the  $\alpha$  and  $\beta$  chain constant region extracellular sequences may correspond to those of a second human TCR. For example, A6 Tax sTCR constant region extracellular sequences can be used as framework onto which heterologous variable domains can be fused.

25

In another embodiment of the invention the TCR  $\alpha$  and  $\beta$  chain variable region sequences present in the  $\alpha$  and  $\beta$  segments together correspond to the functional variable domain of a first TCR, and the TCR  $\alpha$  and  $\beta$  chain constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to those of a second TCR, the first and second TCRs being from different species. In this 30

embodiment it is preferred that the TCR  $\alpha$  and  $\beta$  chain variable region sequences present in the  $\alpha$  and  $\beta$  segments together correspond to the functional variable domain of a human TCR, and the TCR  $\alpha$  and  $\beta$  chain constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to those of a mouse TCR. Such 5 embodiments of the present invention have the advantage that the scTCRs contain non-human constant region sequences which are likely to be immunogenic, and thus are likely to enhance the overall immune response to the dTCR when localised on its target cell. The immune response to aberrant cells such as cancer cells may thus be enhanced.

10

*Linker*

In the present invention, a linker sequence links the  $\alpha$  and  $\beta$  segments, to form a single polypeptide strand. The linker sequence may, for example, have the formula -P-AA-P- wherein P is proline and AA represents an amino acid sequence wherein the amino 15 acids are glycine and serine.

For the scTCR to bind an MHC-peptide complex, the  $\alpha$  and  $\beta$  segments must be paired so that the variable region sequences thereof are orientated for such binding. Hence the linker should have sufficient length to span the distance between the C terminus of the 20  $\alpha$  segment and the N terminus of the  $\beta$  segment, or vice versa. On the other hand excessive linker length should preferably be avoided, in case the end of the linker at the N-terminal variable region sequence blocks or reduces bonding of the scTCR to the target peptide-MHC complex.

25 For example, in the case where the constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to the constant regions of the  $\alpha$  and  $\beta$  chains of a native TCR truncated at their C termini such that the cysteine residues which form the native interchain disulfide bond of the TCR are excluded, and the linker sequence links the C terminus of the  $\alpha$  segment to the N terminus of the  $\beta$  segment, the linker 30 may consist of from 26 to 41, for example 29, 30, 31 or 32 amino acids, and a

particular linker has the formula -PGGG-(SGGGG)<sub>5</sub>-P- wherein P is proline, G is glycine and S is serine.

*Disulfide bond*

5 A principle characterising feature of the scTCRs of the present invention is the disulfide bond between the constant region extracellular sequences of the  $\alpha$  and  $\beta$  segments. That bond may correspond to the native interchain disulfide bond present in native dimeric  $\alpha\beta$  TCRs, or may have no counterpart in native TCRs, being between cysteines specifically incorporated into the constant region extracellular sequences of  
10 the  $\alpha$  and  $\beta$  segments. In some cases, both a native and a non-native disulfide bond may be desirable in the present scTCRs.

15 The position of the disulfide bond is subject to the requirement that the variable region sequences of the  $\alpha$  and  $\beta$  segments are mutually orientated substantially as in native  $\alpha\beta$  T cell receptors.

20 The disulfide bond may be formed by mutating non-cysteine residues on  $\alpha$  and  $\beta$  segments to cysteine, and causing the bond to be formed between the mutated residues. Residues whose respective  $\beta$  carbons are approximately 6 Å (0.6 nm) or less, and preferably in the range 3.5 Å (0.35 nm) to 5.9 Å (0.59 nm) apart in the native TCR are preferred, such that a disulfide bond can be formed between cysteine residues introduced in place of the native residues. It is preferred if the disulfide bond is between residues in the constant immunoglobulin region, although it could be between residues of the membrane proximal region. Preferred sites where cysteines can be  
25 introduced to form the disulfide bond are the following residues in exon 1 of TRAC\*01 for the TCR  $\alpha$  chain and TRBC1\*01 or TRBC2\*01 for the TCR  $\beta$  chain:

TCR $\alpha$ chain	TCR $\beta$ chain	Native $\beta$ carbon separation (nm)
Thr 48	Ser 57	0.473
Thr 45	Ser 77	0.533
Tyr 10	Ser 17	0.359
Thr 45	Asp 59	0.560
Ser 15	Glu 15	0.59

Now that the residues in human TCRs which can be mutated into cysteine residues to form a new interchain disulfide bond in scTCRs according to the invention have been  
 5 identified, those of skill in the art will be able to mutate TCRs of other species in the same way to produce a scTCR of that species. In humans, the skilled person merely needs to look for the following motifs in the respective TCR chains to identify the residue to be mutated (the shaded residue is the residue for mutation to a cysteine).

10                     $\alpha$  Chain Thr 48:            DSDVYITDKTVLDMRSMDFK (amino acids 39-58 of exon 1 of the TRAC\*01 gene)

15                     $\alpha$  Chain Thr 45:            QSKDSDVYITDKTVLDMRSM (amino acids 36-55 of exon 1 of the TRAC\*01 gene)

20                     $\alpha$  Chain Tyr 10:            DIQNPDPAVYQLRDSKSSDK (amino acids 1-20 of exon 1 of the TRAC\*01 gene)

25                     $\alpha$  Chain Ser 15:            DPAVYQLRDSKSSDKSVCLF (amino acids 6-25 of exon 1 of the TRAC\*01 gene)

$\beta$  Chain Ser 57:            NGKEVHSGVSTDQPPLKEQP (amino acids 48- 67 of exon 1 of the TRBC1\*01 & TRBC2\*01 genes)

$\beta$  Chain Ser 77:            ALNDSRYALSSRLRVSATFW (amino acids 68- 87 of exon 1 of the TRBC1\*01 & TRBC2\*01 genes)

**β Chain Ser 17:** PPEVAVFEPESEAISHTQKA(amino acids 8- 27 of exon 1 of the TRBC1\*01 & TRBC2\*01 genes)

5 **β Chain Asp 59:** KEVHSGVSTDQPQLKEQPAL(amino acids 50- 69 of exon 1 of the TRBC1\*01 & TRBC2\*01 genes gene)

**β Chain Glu 15:** VFPPEVAVFEPESEAISHTQ(amino acids 6- 25 of exon 1 of the TRBC1\*01 & TRBC2\*01 genes)

10 In other species, the TCR chains may not have a region which has 100% identity to the above motifs. However, those of skill in the art will be able to use the above motifs to identify the equivalent part of the TCR  $\alpha$  or  $\beta$  chain and hence the residue to be mutated to cysteine. Alignment techniques may be used in this respect. For example, ClustalW, available on the European Bioinformatics Institute website

15 (<http://www.ebi.ac.uk/index.html>) can be used to compare the motifs above to a particular TCR chain sequence in order to locate the relevant part of the TCR sequence for mutation.

20 The present invention includes within its scope  $\alpha\beta$ -analogue scTCRs, as well as those of other mammals, including, but not limited to, mouse, rat, pig, goat and sheep. Also included are human/non-human chimeric scTCRs as discussed above. As mentioned above, those of skill in the art will be able to determine sites equivalent to the above-described human sites at which cysteine residues can be introduced to form an inter-chain disulfide bond. For example, the following shows the amino acid sequences of

25 the mouse  $C\alpha$  and  $C\beta$  soluble domains, together with motifs showing the murine residues equivalent to the human residues mentioned above that can be mutated to cysteines to form a TCR interchain disulfide bond (where the relevant residues are shaded):

30 **Mouse  $C\alpha$  soluble domain:**

PYIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDMK  
AMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVP

Mouse C $\beta$  soluble domain:

5 EDLRNVTTPKVSLEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGREV  
HSGVSTDPAKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDK  
WPEGSPKPVTQNISAEAWGRAD

Murine equivalent of human  $\alpha$  Chain Thr 48: ESGTFITDKTVLDMKAMDSK  
10

Murine equivalent of human  $\alpha$  Chain Thr 45: KTMESGTFITDKTVLDMKAM

Murine equivalent of human  $\alpha$  Chain Tyr 10: YIQNPEPAVYQLKDPRSQDS

15 Murine equivalent of human  $\alpha$  Chain Ser 15: AVYQLKDPRSQDSTLCLFTD

Murine equivalent of human  $\beta$  Chain Ser 57: NGREVHSGVSTDPAKESN

Murine equivalent of human  $\beta$  Chain Ser 77: KESNYSYCLSSRLRVSATFW  
20

Murine equivalent of human  $\beta$  Chain Ser 17: PPKVSLFEPSKAEIANKQKA

Murine equivalent of human  $\beta$  Chain Asp 59: REVHSGVSTDPAKESNYS

25 Murine equivalent of human  $\beta$  Chain Glu 15: VTPPKVSLFEPSKAEIANKQ

As discussed above, the A6 Tax sTCR extracellular constant regions can be used as framework onto which heterologous variable domains can be fused. It is preferred that the heterologous variable region sequences are linked to the constant region sequences  
30 at any point between the disulfide bond and the N termini of the constant region

5 sequences. In the case of the A6 Tax TCR  $\alpha$  and  $\beta$  constant region sequences, the disulfide bond may be formed between cysteine residues introduced at amino acid residues 158 and 172 respectively. Therefore it is preferred if the heterologous  $\alpha$  and  $\beta$  chain variable region sequence attachment points are between residues 159 or 173 and the N terminus of the  $\alpha$  or  $\beta$  constant region sequences respectively.

*Additional Aspects*

10 A scTCR (which is preferably human) of the present invention may be provided in substantially pure form, or as a purified or isolated preparation. For example, it may be provided in a form which is substantially free of other proteins.

15 A plurality of scTCRs of the present invention may be provided in a multivalent complex. Thus, the present invention provides, in one aspect, a multivalent T cell receptor (TCR) complex, which comprises a plurality of soluble T cell receptors as described herein. Each of the plurality of soluble TCRs is preferably identical.

In a further aspect, the invention provides a method for detecting MHC-peptide complexes, which comprises:

20

- a. providing a scTCR of the current invention
- b. contacting the scTCR with the MHC-peptide complexes; and
- detecting binding of the scTCR to the MHC-peptide complexes.

*Therapeutic Use*

25 The scTCR (or multivalent complex thereof) of the present invention may alternatively or additionally be associated with (e.g. covalently or otherwise linked to) a therapeutic agent which may be, for example, a toxic moiety for use in cell killing, or an immunostimulating agent such as an interleukin or a cytokine. A multivalent scTCR complex of the present invention may have enhanced binding capability for a TCR ligand such as a pMHC complex or CD1 molecule compared to a non-multimeric  
30 T cell receptor heterodimer. Thus, the multivalent scTCR complexes according to the invention are particularly useful for tracking or targeting cells presenting particular

antigens *in vitro* or *in vivo*, and are also useful as intermediates for the production of further multivalent TCR complexes having such uses. The scTCR or multivalent scTCR complex may therefore be provided in a pharmaceutically acceptable formulation for use *in vivo*.

5

The invention also provides a method for delivering a therapeutic agent to a target cell, which method comprises contacting potential target cells with a scTCR or multivalent scTCR complex in accordance with the invention under conditions to allow attachment of the scTCR or multivalent scTCR complex to the target cell, said scTCR 10 or multivalent scTCR complex being specific for the MHC-peptide complexes and having the therapeutic agent associated therewith.

In particular, the soluble scTCR or multivalent scTCR complex can be used to deliver therapeutic agents to the location of cells presenting a particular antigen. This would 15 be useful in many situations and, in particular, against tumours. A therapeutic agent could be delivered such that it would exercise its effect locally but not only on the cell it binds to. Thus, one particular strategy envisages anti-tumour molecules linked to T cell receptors or multivalent scTCR complexes specific for tumour antigens.

20 Many therapeutic agents could be employed for this use, for instance radioactive compounds, enzymes (perforin for example) or chemotherapeutic agents (cis-platin for example). To ensure that toxic effects are exercised in the desired location the toxin could be inside a liposome linked to streptavidin so that the compound is released slowly. This will prevent damaging effects during the transport in the body and ensure 25 that the toxin has maximum effect after binding of the scTCR to the relevant antigen presenting cells.

Other suitable therapeutic agents include:

30 • small molecule cytotoxic agents, i.e. compounds with the ability to kill mammalian cells having a molecular weight of less than 700 daltons. Such compounds could also contain toxic metals capable of having a cytotoxic effect.

Furthermore, it is to be understood that these small molecule cytotoxic agents also include pro-drugs, i.e. compounds that decay or are converted under physiological conditions to release cytotoxic agents. Examples of such agents include cis-platin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide, 5 gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodiumphotofrin II, temozolamide, topotecan, trimetrate glucuronate, auristatin E vincristine and doxorubicin;

- 10 • peptide cytotoxins, i.e. proteins or fragments thereof with the ability to kill mammalian cells. Examples include ricin, diphtheria toxin, pseudomonas bacterial exotoxin A, DNAase and RNAase;
- 15 • radio-nuclides, i.e. unstable isotopes of elements which decay with the concurrent emission of one or more of  $\alpha$  or  $\beta$  particles, or  $\gamma$  rays. Examples include iodine 131, rhenium 186, indium 111, yttrium 90, bismuth 210 and 213, actinium 225 and astatine 213;
- 20 • prodrugs, such as antibody directed enzyme pro-drugs;
- immuno-stimulants, i.e. moieties which stimulate immune response. Examples include cytokines such as IL-2, chemokines such as IL-8, platelet factor 4, melanoma growth stimulatory protein, etc, antibodies or fragments thereof, complement activators, xenogeneic protein domains, allogeneic protein domains, viral/bacterial protein domains and viral/bacterial peptides.

Soluble scTCRs or multivalent scTCR complexes of the invention may be linked to an enzyme capable of converting a prodrug to a drug. This allows the prodrug to be converted to the drug only at the site where it is required (i.e. targeted by the scTCR).

25 Examples of suitable MHC-peptide targets for the scTCR according to the invention include, but are not limited to, viral epitopes such as HTLV-1 epitopes (e.g. the Tax peptide restricted by HLA-A2; HTLV-1 is associated with leukaemia), HIV epitopes, EBV epitopes, CMV epitopes; melanoma epitopes (e.g. MAGE-1 HLA-A1 restricted epitope) and other cancer-specific epitopes (e.g. the renal cell carcinoma associated antigen G250 restricted by HLA-A2); and epitopes associated with autoimmune 30

disorders, such as rheumatoid arthritis. Further disease-associated pMHC targets, suitable for use in the present invention, are listed in the HLA Factbook (Barclay (Ed) Academic Press), and many others are being identified.

5 Localising drug delivery through the specificity of scTCRs can potentially enhance a multitude of disease treatments.

Viral diseases for which drugs exist, e.g. HIV, SIV, EBV, CMV, would benefit from the drug being released or activated in the near vicinity of infected cells. For cancer, 10 the localisation in the vicinity of tumours or metastasis would enhance the effect of toxins or immunostimulants. In autoimmune diseases, immunosuppressive drugs could be released slowly, having more local effect over a longer time-span while minimally affecting the overall immuno-capacity of the subject. In the prevention of graft rejection, the effect of immunosuppressive drugs could be optimised in the same 15 way. For vaccine delivery, the vaccine antigen could be localised in the vicinity of antigen presenting cells, thus enhancing the efficacy of the antigen. The method can also be applied for imaging purposes.

The scTCRs of the present invention may be used to modulate T cell activation by 20 binding to specific ligands such as pMHC and thereby inhibiting T cell activation. Autoimmune diseases involving T cell-mediated inflammation and/or tissue damage would be amenable to this approach, for example type I diabetes. Knowledge of the specific peptide epitope presented by the relevant pMHC is required for this use.

25 Medicaments in accordance with the invention will usually be supplied as part of a sterile, pharmaceutical composition which will normally include a pharmaceutically acceptable carrier. This pharmaceutical composition may be in any suitable form, (depending upon the desired method of administering it to a patient). It may be provided in unit dosage form, will generally be provided in a sealed container and may be provided 30 as part of a kit. Such a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.

The pharmaceutical composition may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including 5 subcutaneous, intramuscular, intravenous or intradermal) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by admixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.

*Screening Use.*

10 The scTCRs of the present invention are capable of utilisation in screening methods designed to identify modulators, including inhibitors, of the TCR-mediated cellular immune synapse.

15 As is known to those skilled in the art there are a number of assay formats that provide a suitable basis for protein-protein interaction screens of this type.

Amplified Luminescent Proximity Homogeneous Assay systems such as the AlphaScreen™, rely on the use of "Donor" and "Acceptor" beads that are coated with a layer of hydrogel to which receptor and ligand proteins can be attached. The 20 interaction between these receptor and ligand molecules brings the beads into proximity. When these beads are subject to laser light a photosensitizer in the "Donor" bead converts ambient oxygen to a more excited singlet state. The singlet state oxygen molecules diffuse across to react with a chemiluminescer in the "Acceptor" bead that further activates fluorophores contained within the same bead. The fluorophores 25 subsequently emit light at 520-620 nm, this signals that the receptor-ligand interaction has occurred. The presence of an inhibitor of the receptor-ligand interaction causes this signal to be diminished.

30 Surface Plasmon Resonance (SPR) is an interfacial optical assay, in which one binding partner (normally the receptor) is immobilised on a 'chip' (the sensor surface) and the binding of the other binding partner (normally the ligand), which is soluble and is

caused to flow over the chip, is detected. The binding of the ligand results in an increase in concentration of protein near to the chip surface which causes a change in the refractive index in that region. The surface of the chip is comprised such that the change in refractive index may be detected by surface plasmon resonance, an optical 5 phenomenon whereby light at a certain angle of incidence on a thin metal film produces a reflected beam of reduced intensity due to the resonant excitation of waves of oscillating surface charge density (surface plasmons). The resonance is very sensitive to changes in the refractive index on the far side of the metal film, and it is this signal which is used to detect binding between the immobilised and soluble 10 proteins. Systems which allow convenient use of SPR detection of molecular interactions, and data analysis, are commercially available. Examples are the Iasy<sup>TM</sup> machines (Fisons) and the Biacore<sup>TM</sup> machines.

Other interfacial optical assays include total internal reflectance fluorescence (TIRF), 15 resonant mirror (RM) and optical grating coupler sensor (GCS), and are discussed in more detail in Woodbury and Venton (*J. Chromatog. B.* **725** 113-137 (1999)). The scintillation proximity assay (SPA) has been used to screen compound libraries for inhibitors of the low affinity interaction between CD28 and B7 ( $K_d$  probably in the region of 4  $\mu\text{M}$  (Van der Merwe *et al* *J. Exp. Med.* **185**:393-403 (1997), Jenh *et al*, 20 *Anal Biochem* **165**(2) 287-93 (1998)). SPA is a radioactive assay making use of beta particle emission from certain radioactive isotopes which transfers energy to a scintillant immobilised on the indicator surface. The short range of the beta particles in solution ensures that scintillation only occurs when the beta particles are emitted in close proximity to the scintillant. When applied for the detection of protein-protein 25 interactions, one interaction partner is labelled with the radioisotope, while the other is either bound to beads containing scintillant or coated on a surface together with scintillant. If the assay can be set up optimally, the radioisotope will be brought close enough to the scintillant for photon emission to be activated only when binding between the two proteins occurs.

A further aspect of the invention is a method of identifying an inhibitor of the interaction between an scTCR and a TCR ligand selected from MHC-peptide complexes, CD1-antigen complexes, superantigens and MHC-peptide/superantigen complexes comprising contacting the scTCR with a scTCR ligand binding partner, in 5 the presence of and in the absence of a test compound, and determining whether the presence of the test compound reduces binding of the scTCR to the ligand, such reduction being taken as identifying an inhibitor.

10 A final aspect of the invention is a method of identifying a potential inhibitor of the interaction between an scTCR and TCR ligand selected from MHC-peptide complexes, CD1-antigen complexes, superantigens and MHC-peptide/superantigen complexes comprising contacting the scTCR or scTCR ligand binding partner with a test compound and determining whether the test compound binds to the scTCR and/or 15 the ligand, such binding being taken as identifying a potential inhibitor. This aspect of the invention may find particular utility in interfacial optical assays such as those carried out using the BIAcore™ system.

20 Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*. The prior art documents mentioned herein are incorporated to the fullest extent permitted by law.

#### Examples

25 The invention is further described in the following examples, which do not limit the scope of the invention in any way.

Reference is made in the following to the accompanying drawings in which:

30 Figures 1a and 1b show respectively the nucleic acid sequences of the  $\alpha$  and  $\beta$  chains of a soluble A6 TCR, mutated so as to introduce a cysteine codon. The shading

indicates the introduced cysteine codons;

5 Figure 2a shows the A6 TCR  $\alpha$  chain extracellular amino acid sequence, including the  $T_{48} \rightarrow C$  mutation (underlined) used to produce the novel disulphide inter-chain bond, and Figure 2b shows the A6 TCR  $\beta$  chain extracellular amino acid sequence, including the  $S_{57} \rightarrow C$  mutation (underlined) used to produce the novel disulphide inter-chain bond;

10 Figure 3 shows the DNA and amino acid sequence of the Gly/Ser linker (30mer)

Figure 4 summarises the cloning strategy used to produce the scDiS A6 TCR

Figure 5a shows the DNA sequence of the scDiS A6 TCR.

15 Figure 5b shows the amino acid sequence of the scDiS A6 TCR.

Figure 6 illustrates the elution of the scDiS A6 TCR protein from a POROS 50HQ ion exchange column using a 0-500 mM NaCl gradient, as indicated by the straight line;

20 Figure 7 shows the results of both reducing SDS-PAGE (Coomassie-stained) and non-reducing SDS-PAGE (Coomassie-stained) gels of fractions A15, B10, B9 and B3 from the column run illustrated by Figure 6. Fractions B9 and B10 clearly contain protein corresponding to the expected size of the scDiS A6 TCR;

25 Figure 8 illustrates the elution of the scDiS A6 TCR elution from a Superdex 200 gel filtration column of fractions B10-B7 from the ion exchange column run shown in Figure 6;

30 Figure 9 shows the results of both reducing SDS-PAGE (Coomassie-stained) and non-reducing SDS-PAGE (Coomassie-stained) gels of fractions B8, B7, B3 and B2 from

the gel filtration column run illustrated by Figure 8. Fraction B7 clearly contains protein corresponding to the expected size of the scDiS A6 TCR;

5 Figure 10 is a final gel filtration run into BIACore buffer of the concentrated fractions B9-B6 of the gel filtration run shown in Figure 8. The scDiS A6 TCR elutes as a single major peak;

Figure 11 BIACore data for binding of the scDiS A6 TCR to HLA-A2 TAX;

*Example 1 – Design of primers and mutagenesis of A6 Tax TCR  $\alpha$  and  $\beta$  chains to introduce the cysteine residues required for the formation of a novel inter-chain disulphide bond*

5 For mutating A6 Tax threonine 48 of exon 1 in TRAC\*01 to cysteine, the following primers were designed (mutation shown in lower case):

5'-C ACA GAC AAA tgT GTG CTA GAC AT  
5'-AT GTC TAG CAC Aca TTT GTC TGT G

10 For mutating A6 Tax serine 57 of exon 1 in both TRBC1\*01 and TRBC2\*01 to cysteine, the following primers were designed (mutation shown in lower case):

5'-C AGT GGG GTC tGC ACA GAC CC  
15 5'-GG GTC TGT GCa GAC CCC ACT G

*PCR mutagenesis:*

Expression plasmids containing the genes for the A6 Tax TCR  $\alpha$  or  $\beta$  chain were mutated using the  $\alpha$ -chain primers or the  $\beta$ -chain primers respectively, as follows.

20 100 ng of plasmid was mixed with 5  $\mu$ l 10 mM dNTP, 25  $\mu$ l 10xPfu-buffer (Stratagene), 10 units Pfu polymerase (Stratagene) and the final volume was adjusted to 240  $\mu$ l with H<sub>2</sub>O. 48  $\mu$ l of this mix was supplemented with primers diluted to give a final concentration of 0.2  $\mu$ M in 50  $\mu$ l final reaction volume. After an initial denaturation step of 30 seconds at 95°C, the reaction mixture was subjected to 15 rounds of denaturation (95°C, 30 sec.), annealing (55°C, 60 sec.), and elongation (73°C, 8 min.) in a Hybaid PCR express PCR machine. The product was then digested for 5 hours at 37°C with 10 units of DpnI restriction enzyme (New England Biolabs). 10  $\mu$ l of the digested reaction was transformed into competent XL1-Blue bacteria and grown for 18 hours at 37°C. A single colony was picked and grown over night in 5 ml

25 30 TYP + ampicillin (16 g/l Bacto-Tryptone, 16 g/l Yeast Extract, 5 g/l NaCl, 2.5 g/l

K<sub>2</sub>HPO<sub>4</sub>, 100 mg/l Ampicillin). Plasmid DNA was purified on a Qiagen mini-prep column according to the manufacturer's instructions and the sequence was verified by automated sequencing at the sequencing facility of Department of Biochemistry, Oxford University. The respective mutated nucleic acid and amino acid sequences are  
5 shown in Figures 1a and 2a for the  $\alpha$  chain and Figures 1b and 2b for the  $\beta$  chain.

*Example 2 – Design, Expression and testing of a single-chain A6 TCR incorporating a novel disulphide inter-chain bond.*

5 The expression vectors containing the DNA sequences of the mutated A6 TCR  $\alpha$  and  $\beta$  chains incorporating the additional cysteine residues required for the formation of a novel disulphide prepared in Example 1 and as shown in figures 1a and 1b were used as the basis for the production of a single-chain A6 TCR , with the exception that the stop codon (TAA) was removed from the end of the  $\alpha$  chain sequence, as follows:

10 10 The scDiS A6 TCR contains a 30 amino acid linker sequence between the C-terminus of the TCR  $\alpha$  chain and the N-terminus of the  $\beta$  chain. Figure 3 shows the DNA and amino acid sequence of this linker. The cloning strategy employed to produce the scDiS A6 TCR is summarised in Figure 4.

15 15 Briefly, the alpha and beta chains of the A6 dsTCR were amplified by PCR using primers containing restriction sites as shown in figure 4, ie.:

Alpha 5' primer: ccaaggccatatgcagaaggaagtggagcagaactct  
Alpha 3' primer: ttggggcccgccggatccgcggggggaaactttctgggctgggg  
20 Beta 5' primer: tccccggggggcgatccggcgggcccaacgctggtgtcactcag  
Beta 3' primer: gggaaagcttagtctgctctaccccaggcctcg

25 The Two fragments thus generated were PCR stitched using the 5' alpha and 3' beta primers to give a single-chain TCR with a short linker containing the sites XmaI-BamHI-ApaI. This fragment was cloned into pGMT7. The full length linker was then inserted in two stages, firstly a 42bp fragment was inserted using the XmaI and BamHI sites:

30 5' -CC GGG GGT GGC TCT GGC GGT TCA GGC GGT GGC G -3'  
3' - C CCA CCG AGA CCG CCA CCG CCA AGT CCG CCA CCG CCT AG-5'

Secondly, a 48bp fragment was inserted using the BamHI and ApaI sites to create a 90bp linker between the 3' end of the alpha chain and the 5' end of the beta chain. The 48bp fragment was made by PCR extension of a mixture of the following oligos:

5

5' - GC GGA TCC GGC GGT GGC GGT TCG GGT GGC GGT GGC TC-3'  
3' - CCA AGC CCA CCG CCA CCG AGT CCG CCA CCG CCC GGG TG -5'

10 The product of this extension was digested with BamHI and ApaI and ligated into the digested plasmid containing the 42bp linker fragment.

15 The complete DNA and amino acid sequence of the scDiS A6 TCR is shown in Figures 5a and 5b respectively.

*Expression and Purification of single-chain disulphide linked A6 TCR:*

15 The expression plasmid containing the single-chain disulphide linked A6 TCR was transformed into *E.coli* strain BL21pLysS, and single ampicillin-resistant colonies were grown at 37°C in TYP (ampicillin 100µg/ml) medium to OD<sub>600</sub> of 0.4 before inducing protein expression with 0.5mM IPTG. Cells were harvested three hours post-induction by centrifugation for 30 minutes at 4000rpm in a Beckman J-6B. Cell 20 pellets were re-suspended in a buffer containing 50mM Tris-HCl, 25% (w/v) sucrose, 1mM NaEDTA, 0.1% (w/v) NaAzide, 10mM DTT, pH 8.0. After an overnight freeze-thaw step, re-suspended cells were sonicated in 1 minute bursts for a total of around 10 minutes in a Milsonix XL2020 sonicator using a standard 12mm diameter probe. Inclusion body pellets were recovered by centrifugation for 30 minutes at 13000rpm in 25 a Beckman J2-21 centrifuge. Three detergent washes were then carried out to remove cell debris and membrane components. Each time the inclusion body pellet was homogenised in a Triton buffer (50mM Tris-HCl, 0.5% Triton-X100, 200mM NaCl, 10mM NaEDTA, 0.1% (w/v) NaAzide, 2mM DTT, pH 8.0) before being pelleted by centrifugation for 15 minutes at 13000rpm in a Beckman J2-21. Detergent and salt 30 was then removed by a similar wash in the following buffer: 50mM Tris-HCl, 1mM NaEDTA, 0.1% (w/v) NaAzide, 2mM DTT, pH 8.0. Finally, the inclusion bodies were divided into 30 mg aliquots and frozen at -70°C. Inclusion body protein yield

was quantitated by solubilising with 6M guanidine-HCl and measurement with a Bradford dye-binding assay (PerBio).

5       Approximately 15mg of the solubilised inclusion body chain was thawed from frozen stocks. The inclusion bodies were diluted to a final concentration of 5mg/ml in 6M guanidine solution, and DTT (2M stock) was added to a final concentration of 10mM. The mixture was incubated at 37°C for 30 min. 1 litre of the following refolding buffer: 100mM Tris pH 8.5, 400mM L-Arginine, 2mM EDTA, 5mM reduced Glutathione, 0.5mM oxidised Glutathione, 5M urea, 0.2mM PMSF was prepared and 10     stirred vigourously at 5°C ± 3°C. The redox couple (2-mercaptoethylamine and cystamine (to final concentrations of 6.6mM and 3.7mM, respectively) were added approximately 5 minutes before addition of the denatured TCR chains. The protein was then allowed to refold for approximately 5 hours ± 15 minutes with stirring at 5°C ± 3°C. The refold was then dialysed twice, firstly against 10 litres of 100mM urea, 15     secondly against 10 litres of 100mM urea, 10mM Tris pH 8.0. Both refolding and dialysis steps were carried out at 6-8°C.

20     scTCR was separated from degradation products and impurities by loading the dialysed refold onto a POROS 50HQ anion exchange column and eluting bound protein with a gradient of 0-500mM NaCl over 50 column volumes using an Akta purifier (Pharmacia) as in Figure 6. Peak fractions were stored at 4°C and analysed by Coomassie-stained SDS-PAGE (Figure 7) before being pooled and concentrated. The sTCR was then purified and characterised using a Superdex 200HR gel filtration column (Figure 8) pre-equilibrated in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.5 mM EDTA, 0.05% nonidet p40). Peak fractions were stored at 4°C and 25     analysed by Coomassie-stained SDS-PAGE (Figure 9) before being pooled and concentrated. Finally, concentrated fractions B9-B6 were run put through another gel filtration step in order to produce purified protein in BIACore buffer, (Figure 10) The peak eluting at a relative molecular weight of approximately 50 kDa was pooled. This 30     was concentrated prior to characterisation by BIACore surface plasmon resonance analysis.

*Example 3 - BIACore surface plasmon resonance characterisation of scTCR binding to HLA-A2 Tax*

A surface plasmon resonance biosensor (BIACore 3000<sup>TM</sup>) was used to analyse the 5 binding of the A6 scTCR to its peptide-MHC ligand (HLA-A2 Tax). This was facilitated by producing single pMHC complexes (described below) which were immobilised to a streptavidin-coated binding surface in a semi-oriented fashion, allowing efficient testing of the binding of a soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously. Manual 10 injection of HLA complex allows the precise level of immobilised class I molecules to be manipulated easily.

Such immobilised complexes are capable of binding both T-cell receptors and the coreceptor CD8 $\alpha\alpha$ , both of which may be injected in the soluble phase.

15 Biotinylated class I HLA-A2 - Tax complexes were refolded *in vitro* from bacterially-expressed inclusion bodies containing the constituent subunit proteins and synthetic peptide, followed by purification and *in vitro* enzymatic biotinylation (O'Callaghan *et al.* (1999) *Anal. Biochem.* 266: 9-15). HLA-heavy chain was expressed with a C-terminal biotinylation tag which replaces the transmembrane and cytoplasmic domains 20 of the protein in an appropriate construct. The HLA light-chain or  $\beta$ 2-microglobulin was also expressed as inclusion bodies in *E.coli* from an appropriate construct, at a level of ~500 mg/litre bacterial culture.

25 *E. coli* cells were lysed and inclusion bodies are purified to approximately 80% purity. Protein from inclusion bodies was denatured in 6 M guanidine-HCl, 50 mM Tris pH 8.1, 100 mM NaCl, 10 mM DTT, 10 mM EDTA, and was refolded at a concentration of 30 mg/litre heavy chain, 30 mg/litre  $\beta$ 2m into 0.4 M L-Arginine-HCl, 100 mM Tris pH 8.1, 3.7 mM cystamine, mM cysteamine, 4 mg/ml peptide (e.g. tax 11-19), by 30 addition of a single pulse of denatured protein into refold buffer at < 5°C. Refolding was allowed to reach completion at 4°C for at least 1 hour.

Buffer was exchanged by dialysis in 10 volumes of 10 mM Tris pH 8.1. Two changes of buffer were necessary to reduce the ionic strength of the solution sufficiently. The protein solution was then filtered through a 1.5 $\mu$ m cellulose acetate filter and loaded

5 onto a POROS 50HQ anion exchange column (8 ml bed volume). Protein was eluted with a linear 0-500 mM NaCl gradient. HLA-A2-peptide complex eluted at approximately 250 mM NaCl, and peak fractions were collected, a cocktail of protease inhibitors (Calbiochem) was added and the fractions were chilled on ice.

10 Biotinylation tagged HLA complexes were buffer exchanged into 10 mM Tris pH 8.1, 5 mM NaCl using a Pharmacia fast desalting column equilibrated in the same buffer. Immediately upon elution, the protein-containing fractions were chilled on ice and protease inhibitor cocktail (Calbiochem) was added. Biotinylation reagents were then added: 1 mM biotin, 5 mM ATP (buffered to pH 8), 7.5 mM MgCl<sub>2</sub>, and 5  $\mu$ g/ml

15 BirA enzyme (purified according to O'Callaghan *et al.* (1999) *Anal. Biochem.* **266**: 9-15). The mixture was then allowed to incubate at room temperature overnight.

Biotinylated HLA complexes were purified using gel filtration chromatography. A Pharmacia Superdex 75 HR 10/30 column was pre-equilibrated with filtered PBS and

20 1 ml of the biotinylation reaction mixture was loaded and the column was developed with PBS at 0.5 ml/min. Biotinylated HLA complexes eluted as a single peak at approximately 15 ml. Fractions containing protein were pooled, chilled on ice, and protease inhibitor cocktail was added. Protein concentration was determined using a Coomassie-binding assay (PerBio) and aliquots of biotinylated HLA complexes were

25 stored frozen at -20°C. Streptavidin was immobilised by standard amine coupling methods.

The interactions between A6 Tax scTCR containing a novel inter-chain bond and its ligand/ MHC complex or an irrelevant HLA-peptide combination, the production of

30 which is described above, were analysed on a BIAcore 3000™ surface plasmon resonance (SPR) biosensor. SPR measures changes in refractive index expressed in

response units (RU) near a sensor surface within a small flow cell, a principle that can be used to detect receptor ligand interactions and to analyse their affinity and kinetic parameters. The probe flow cells were prepared by immobilising the individual HLA-peptide complexes in separate flow cells via binding between the biotin cross linked onto  $\beta$ 2m and streptavidin which have been chemically cross linked to the activated surface of the flow cells. The assay was then performed by passing scTCR over the surfaces of the different flow cells at a constant flow rate, measuring the SPR response in doing so. Injections of soluble sTCR at constant flow rate and different concentrations over the peptide-HLA complex were used to define the background resonance. The values of these control measurements were subtracted from the values obtained with specific peptide-HLA complex and used to calculate binding affinities expressed as the dissociation constant,  $K_d$  (Price & Dwek, Principles and Problems in Physical Chemistry for Biochemists (2<sup>nd</sup> Edition) 1979, Clarendon Press, Oxford).

15 The BIACore analysis of the scDiS A6 TCR demonstrated that this molecule bound specifically to its cognate ligand (HLA-A2 TAX) with a  $k_d$  of  $12.4 \pm 1.62 \mu\text{M}$ .

## Claims:

1. A single chain T cell receptor (scTCR) comprising
  - 5 an  $\alpha$  segment constituted by a TCR  $\alpha$  chain variable region sequence fused to the N terminus of a TCR  $\alpha$  chain constant region extracellular sequence ,  
a  $\beta$  segment constituted by a TCR  $\beta$  chain variable region fused to the N terminus of a TCR  $\beta$  chain constant region extracellular sequence sequence, and
  - 10 a linker sequence linking the C terminus of the  $\alpha$  segment to the N terminus of the  $\beta$  segment, or vice versa,  
the constant region extracellular sequences of the  $\alpha$  and  $\beta$  segments being linked by a disulfide bond,
  - 15 the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the  $\alpha$  and  $\beta$  segments are mutually orientated substantially as in native  $\alpha\beta$  T cell receptors.
- 20 2. A scTCR as claimed in claim 1 wherein a disulfide bond linking constant region extracellular sequences of the  $\alpha$  and  $\beta$  segments is one which has no equivalent in native  $\alpha\beta$  T cell receptors.
- 25 3. A scTCR as claimed in claim 1 or claim 2 wherein a disulfide bond links amino acid residues in sub-sequences of the  $\alpha$  and  $\beta$  segments corresponding to sequences present in the extracellular constant Ig domains of TCR  $\alpha$  and  $\beta$  chains.
- 30 4. A scTCR as claimed in claim 3 wherein the disulfide bond links cysteine residues substituted for amino acid residues whose  $\beta$  carbon atoms are less than 0.6

nm apart in corresponding sequences of the extracellular constant Ig domains of TCR  $\alpha$  and  $\beta$  chains

5. A scTCR as claimed in claim 3 or claim 4 wherein the constant region extracellular sequence present in the  $\alpha$  segment includes a sequence corresponding to the extracellular constant Ig domain of a TCR  $\alpha$  chain, and/or the constant region extracellular sequence present in the  $\beta$  segments includes a sequence corresponding to the extracellular constant Ig domain of a TCR  $\beta$  chain.
- 10 6. A scTCR as claimed in any of the preceding claims wherein (a) the  $\alpha$  segment is the variable region of a TCR fused to the N terminus of the extracellular domain of the  $\alpha$  chain constant region of a TCR  $\alpha$  chain; and/or (b) the  $\beta$  segment is the variable region of a TCR  $\beta$  chain fused to the N terminus of the extracellular domain of the constant region of a TCR  $\beta$  chain.
- 15 7. A scTCR as claimed in any of claims 1 to 5 wherein the constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to the constant regions of the  $\alpha$  and  $\beta$  chains of a native TCR truncated at their C termini such that the cysteine residues which form the native interchain disulfide bond of the TCR are excluded.
- 20 8. A scTCR as claimed in any of claims 1 to 5 wherein the constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to the constant regions of the  $\alpha$  and  $\beta$  chains of a native TCR in which cysteine residues which form the native interchain disulfide bond are substituted by another amino acid residue.
- 25 9. A scTCR as claimed in claim 8, wherein the said cysteine residues are substituted by serine or alanine.

10. A scTCR as claimed in any of the preceding claims wherein the linker sequence has the formula -P-AA-P- wherein P is proline and AA represents an amino acid sequence wherein the amino acids are glycine and serine.

5 11. A scTCR as claimed in any of the preceding claims wherein the linker sequence links the C terminus of the  $\alpha$  domain to the N terminus of the  $\beta$  domain.

12. A scTCR as claimed in claim 11 wherein the linker sequence consists of from 26 to 41 amino acids.

10 14. A scTCR as claimed in claim 11 wherein the linker sequence consists of 29, 30, 31 or 32 amino acids.

15 15. A scTCR as claimed in claim 11 wherein the linker sequence consists of 33, 34, 35 or 36 amino acids.

16. A scTCR as claimed in claim 11 wherein the linker sequence is -PGGG-(SGGGG)<sub>5</sub>-P- wherein P is proline, G is glycine and S is serine.

20 17. A scTCR as claimed in claim 11 wherein the linker sequence is -PGGG-(SGGGG)<sub>6</sub>-P- wherein P is proline, G is glycine and S is serine.

18. A sTCR as claimed in any of the preceding claims in which an unpaired cysteine residue present in native TCR  $\beta$  chain is not present.

25 19. A scTCR as claimed in any preceding claim, wherein the constant region extracellular sequence of the  $\alpha$  segment includes a sequence corresponding to TRAC\*01 and the  $\beta$  segment includes a sequence corresponding to TRBC1\*01 or TRBC2\*01, and the said non-native disulfide bond is between cysteine residues substituted for Thr 48 of exon 1 of TRAC\*01 and Ser 57 of exon 1 of TRBC1\*01 or TRBC2\*01.

30

20. A scTCR as claimed in any one of claims 1 to 19, wherein a disulfide bond links cysteine residues substituted for Thr 45 of exon 1 of TRAC\*01 and Ser 77 of exon 1 of TRBC1\*01 or TRBC2\*01.

5

21. A scTCR as claimed in any one of claims 1 to 19, wherein a disulfide bond links cysteine residues substituted for Tyr 10 of exon 1 of TRAC\*01 and Ser 17 of exon 1 of TRBC1\*01 or TRBC2\*01.

10

22. A scTCR as claimed in any one of claims 1 to 19, wherein a disulfide bond links cysteine residues substituted for Thr 45 of exon 1 of TRAC\*01 and Asp 59 of exon 1 of TRBC1\*01 or TRBC2\*01.

15

23. A scTCR as claimed in any one of claims 1 to 19, wherein a disulfide bond links cysteine residues substituted for Ser 15 of exon 1 of TRAC\*01 and Glu 15 of exon 1 of TRBC1\*01 or TRBC2\*01.

20

24. A scTCR as claimed in any of the preceding claims, wherein the TCR  $\alpha$  and  $\beta$  chain variable region sequences present in the  $\alpha$  and  $\beta$  segments together correspond to the functional variable domain of a first TCR, and the TCR  $\alpha$  and  $\beta$  chain constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to those of a second TCR, the first and second TCRs being from the same species.

25

25. A scTCR as claimed in any of claims 1 to 23, wherein the TCR  $\alpha$  and  $\beta$  chain variable region sequences present in the  $\alpha$  and  $\beta$  segments together correspond to the functional variable domain of a first TCR, and the TCR  $\alpha$  and  $\beta$  chain constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to those of a second TCR, the first and second TCRs being from different species.

26. A scTCR as claimed in claim 25 wherein the TCR  $\alpha$  and  $\beta$  chain variable region sequences present in the  $\alpha$  and  $\beta$  segments together correspond to the functional variable domain of a human TCR, and the TCR  $\alpha$  and  $\beta$  chain constant region extracellular sequences present in the  $\alpha$  and  $\beta$  segments correspond to those of a mouse TCR.

5

27. A scTCR as claimed in claim 25 wherein the TCR is one which binds a peptide MHC complex.

10 28. A scTCR as claimed in claim 25 wherein the TCR is one which binds a CD1-antigen complex.

29. A scTCR as claimed in claim 25 wherein the TCR is one which binds a superantigen or a peptide- MHC/superantigen complex.

15 30. A multivalent T cell receptor (TCR) complex comprising a plurality of sTCRs as claimed in any preceding claim.

31. A scTCR as claimed in any of claims 1 to 29 or a complex as claimed in claim 20 which is covalently linked to a therapeutic agent.

32. A scTCR as claimed in any of claims 1 to 29 or 31, or a plurality thereof, when attached to a particle or bead.

25 33. A composition comprising a scTCR as claimed in any of the preceding claims and a pharmaceutically acceptable carrier.

34. A method for detecting a TCR ligand selected from MHC-peptide complexes, CD1-antigen complexes, superantigens and MHC-peptide/superantigen complexes which comprises: providing a scTCR as claimed in any one of claims 1 to 29, or a 30

plurality thereof; contacting the scTCR with the TCR ligand; and detecting binding of the scTCR to the ligand.

35. A method of identifying an inhibitor of the interaction between an scTCR as claimed in any one of claims 1 to 29, or a plurality thereof, and a TCR ligand selected from MHC-peptide complexes, CD1-antigen complexes, superantigens and MHC-peptide/superantigen complexes comprising contacting the scTCR with a scTCR ligand binding partner, in the presence of and in the absence of a test compound, and determining whether the presence of the test compound reduces binding of the scTCR to the TCR ligand, such reduction being taken as identifying an inhibitor.

10  
15  
36. A method of identifying a potential inhibitor of the interaction between an scTCR as claimed in any one of claims 1 to 29, or a plurality thereof, and a TCR ligand selected from MHC-peptide complexes, CD1-antigen complexes, superantigens and MHC-peptide/superantigen complexes comprising contacting the scTCR or scTCR ligand binding partner with a test compound and determining whether the test compound binds to the scTCR and/or the TCR ligand, such binding being taken as identifying a potential inhibitor.

20  
37. A nucleic acid molecule comprising a sequence encoding a scTCR as claimed in any one of claims 1 to 29, or a sequence complementary thereto.

38. A vector comprising a nucleic acid molecule as claimed in claim 37.

1/8

**Figure 1a**

atgcagaaggaagtggagcagaactctggaccctcagtgttccagagggagccatt  
gcctctctcaactgcacttacagtgaccgaggcccagtccttcttctggtacaga  
caatattctggaaaagccctgagttgataatgtccatatactccaatggtacaaa  
gaagatggaaggttacagcacagctcaataaagccagccagttatgtttctgctc  
atcagagactcccagccagtgattcagccacccatctgtgcgcgttacaactgac  
agctggggaaattgcagttggagcaggcaccagggttgcgtcaccaggatatac  
cagaaccctgaccctgcgttaccagctgagagactctaaatccagtgacaagtct  
gtctgcctattcaccgatttgcatttgcattcaaaatgtgcacaaggatattct  
gatgttatatcacagacaatgtgtctagacatgaggctatggacttcaagagc  
aacagtgtgtggcctggagcaacaaatctgactttgcattgtcacaacgccttcaac  
aacagcattattcagaagacacccatcttcccccagccagaaagttcctaa

**Figure 1b**

atgaacgctggtgtcactcagacccaaaattccaggcctgaagacaggacagagc  
atgacactgcagtgtgcaggataatgaaaccatgaatacatgtcctggtatcgacaa  
gacccaggcatgggctgaggctgattcattactcagttggctgttatcactgac  
caaggagaagtcccaatggctacaatgtctccagatcaaccacagaggattcccg  
ctcaggctgtcggtcgctccctccagacatctgttacttctgtgcaggcagg  
ccggactagcgggagggcgaccagagcagtacttcggccggcaccaggctcagc  
gtcacagaggacctgaaaaacgtgtcccacccggatggctgtgtttgagccatca  
gaagcagagatctccacacccaaaaggccacactgggtgcctggccacaggcttc  
tacccggaccacgtggagctgagctgggtgggtgaatggaaaggaggtgcacagtgg  
gtctgcacagacccgcagccctcaaggagcagccgcctcaatgactccagatac  
gctctgagcagccgcctgaggctcgccacccatctggcaggacccggcaaccac  
ttccgctgtcaagtccagttctacggctctcgagaaatgacgagtgacggaccaggat  
agggccaaacccgtcaccagatcgtcagcggccgaggcctgggttagagcagactaa

**Figure 2a**

MQ  
K<sub>1</sub>EVEQNSGPL SVPEGAIASL NCTYSDRGSQ SFFWYRQYSG KSPELIMSIY  
SNGDKEDGRF TAQLNKASQY VSLLIRDSQP SDSATYLCAV TTDSWGKLQF  
GAGTQVVVTP DIQNPDPAVY QLRDSKSSDK SVCLFTDFDS QTNVSQSKDS  
DVYITDKCVL DMRSMDFKSN SAVAWSNKSD FACANAFNNS IIPEDTFFPS  
PESS\*

**Figure 2b**

M  
N<sub>1</sub>AGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG MGLRLIHYSV  
GAGITDQGEV PNGYNVSRST TEDFPLRLS AAPSQTSVYF CASRPGLAGG  
RPEQYFGPGT RLTVTEDLKN VFPPEVAVFE PSEAEISHTQ KATLVCLATG  
FYPDHVELSW WVNGKEVHSG VCTDPQPLKE QPALNDSRYA LSSRLRVSAT  
FWQDPRNHFR CQVQFYGLSE NDEWTQDRAK PVTQIVSAEA WGRAD\*

6045784.060503

3/8

P G G G S G G G G S G G G G G  
CCC GGG GGT GGC TCT GGC GGT GGC GGT TCA GGC GGT GGC GGA  
GGG CCC CCA CCG AGA CCG CCA CCG CCA AGT CCG CCA CCG CCT

S G G G S G G G G S G G G G  
TCC GGC GGT GGC GGT TCG GGT GGC GGT GGC TCA GGC GGT GGC  
AGG CCG CCA CCG CCA AGC CCA CCG CCA CCG AGT CCG CCA CCG

G P  
GGG CCC  
CCC GGG

**Figure 3**

4/8

Figure 4




Figure 5a

Figure 5b




Figure 6




Figure 7

60475784 . 060503

7/8




Figure 8




Figure 9

60475784 060503




Figure 10




Figure 11

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**